Loading...
Loading...
BIVI| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 57.3K |
| Gross Profit | -57.3K |
| Operating Expense | 7,679.9K |
| Operating I/L | -7,737.3K |
| Other Income/Expense | -335.8K |
| Interest Income | 183.9K |
| Pretax | -8,067.8K |
| Income Tax Expense | -0.0K |
| Net Income/Loss | -8,954.3K |
BioVie Inc. is a clinical stage biotechnology company focused on the discovery, development, and commercialization of drug therapies. Its pipeline includes BIV201, a treatment for ascites due to chronic liver cirrhosis, and NE3107, being developed for Alzheimer's disease, Parkinson's disease, multiple myeloma, and prostate cancer. The company generates revenue through the development and potential commercialization of these drug candidates, targeting significant unmet medical needs in various disease areas.
